Source: Emulate Blog

Emulate Blog Ocaliva, Azelaprag, and the Continuing Challenge of Drug-Induced Liver Injury: A Call for Human-Relevant Models

Drug-induced liver injury (DILI) remains a persistent challenge in drug development, endangering patient safety and delaying the availability of critical therapies. Just days ago, the FDA issued a warning about […] The post Ocaliva, Azelaprag, and the Continuing Challenge of Drug-Induced Liver Injury: A Call for Human-Relevant Models appeared first on Emulate.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Jim Corbett's photo - CEO of Emulate

CEO

Jim Corbett

CEO Approval Rating

55/100

Read more